Heron Therapeutics Aktie
WKN DE: A1XB6K / ISIN: US4277461020
08.05.2015 18:13:47
|
Heron Loss Widens
(RTTNews) - Heron Therapeutics Inc (HRTX) on Friday reported first-quarter net loss of $20.6 million or $0.70 per share compared with a loss of $17.5 million or $0.74 per share last year.
Analysts polled by Thomson Reuters estimated a loss of $0.68 per share for the quarter. Analysts' estimates typically exclude special items.
The wider loss was primarily due to costs associated with the company's recently completed Phase 1 clinical study for HTX-011 - its lead product candidate for the prevention of post-operative pain. It also incurred costs for the ongoing Phase 3 HEC study for SUSTOL.
As of March 31, the company had about $55.6 million in cash.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Heron Therapeutics Incmehr Nachrichten
26.02.25 |
Ausblick: Heron Therapeutics vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
11.11.24 |
Ausblick: Heron Therapeutics gibt Ergebnis zum abgelaufenen Quartal bekannt (finanzen.net) |
Analysen zu Heron Therapeutics Incmehr Analysen
Aktien in diesem Artikel
Heron Therapeutics Inc | 2,13 | 2,61% |
|